Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case 39% Improvement Relative Risk c19early.org/d Rodríguez-Vidales et al. Vitamin D Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 297 patients in Mexico (March - September 2020) Lower severe cases with higher vitamin D levels (not stat. sig., p=0.21) Rodríguez-Vidales et al., Nutrición Hospitalaria, doi:10.20960/nh.03731 Favors vitamin D Favors control
Severe COVID-19 patients have severe vitamin D deficiency in Northeast Mexico
Rodríguez-Vidales et al., Nutrición Hospitalaria, doi:10.20960/nh.03731
Rodríguez-Vidales et al., Severe COVID-19 patients have severe vitamin D deficiency in Northeast Mexico, Nutrición Hospitalaria, doi:10.20960/nh.03731
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 181 diagnostic center patients and 116 ICU patients in Mexico, showing higher risk of severity with vitamin D levels <10ng/mL.
risk of severe case, 38.9% lower, RR 0.61, p = 0.21, high D levels (≥10ng/mL) 89 of 265 (33.6%), low D levels (<10ng/mL) 27 of 32 (84.4%), NNT 2.0, adjusted per study, inverted to make RR<1 favor high D levels (≥10ng/mL), odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rodríguez-Vidales et al., 24 Feb 2022, retrospective, Mexico, peer-reviewed, 8 authors, study period March 2020 - September 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Los pacientes graves con COVID-19 tienen deficiencia grave de vitamina D en el noreste de México Severe COVID-19 patients have severe vitamin D deficiency in Northeast Mexico 10.20960/nh.03731 02/24/2022 OR 3731 Severe COVID-19 patients have severe vitamin D deficiency in Northeast Mexico Los pacientes graves con COVID-19 tienen deficiencia grave de vitamina D en el noreste de México Edgar P. Rodríguez-Vidales1, Denise Garza-Carrillo1, Ana M. SalinasMartínez2,3, Olivia A. Robles-Rodríguez1, Roberto Montes de Oca-Luna 1, Consuelo Treviño-Garza4, Alma R. Marroquín-Escamilla1, and Manuel E. de la O-Cavazos4 Secretaría de Salud de Nuevo León. 1 Unidad de Investigación en 2 Epidemiología y Servicios de Salud. Instituto Mexicano del Seguro Social. Facultad de Salud Publica y Nutrición. Universidad Autónoma de Nuevo 3 León. Departamento de Pediatría. Hospital Universitario Dr. José 4 Eleuterio González. Universidad Autónoma de Nuevo León. Monterrey, Nuevo León. Mexico Received: 23/08/2021 Accepted: 18/01/2022 Correspondence: Manuel E. De la O-Cavazos; Alma R. MarroquínEscamilla. Torre Administrativa, Piso 8. Calle Washington, 2000. Col. Obrera. 64000 Monterrey, Nuevo León. Mexico e-mail: publicacion.investssnl@gmail.com; alma.marroquin@saludnl.gob.mx Conflicts of interests: the authors declare no conflicts of interest. Author contributions: conceptualization, methodology and formal analysis: ERV, RMDOL, and DGC; writing—original draft preparation, data curation, formal analysis: ORR and ASM; design, analysis, writing— review and editing: MDOC, CTG and AME. All authors have read and agreed to the published version of the manuscript. ABSTRACT Objective: the association between vitamin D and COVID-19 severity is not consistent. We compared prevalences and analyzed the association between vitamin D deficiency and COVID-19 severity in Northeast Mexico. Methods: this was a cross-sectional study with individuals consecutively included at a referral diagnostic center during March-September 2020 (n = 181). Concurrently, every patient admitted to intensive care was also consecutively included (n = 116). Serum 25(OH)D < 20 ng/mL was considered vitamin D deficiency. Descriptive, ANOVA, and multivariate ordinal regression analyses were performed. Results: vitamin D deficiency prevalence was 63.8 % (95 % CI, 54.7, 72.0) in severe COVID-19; 25.6 % (95 % CI, 17.4, 36.0) in mild COVID-19; and 42.4 % (95 % CI, 33.2, 52.3) in non-diseased individuals. Vitamin D deficiency increased 5 times the odds of severe COVID-19 (95 % CI, 1.1, 24.3), independently of sex, age, body mass index, and inflammatory markers. Conclusions: this study is the first report of vitamin D deficiency in Northeast Mexico. Vitamin D deficiency was associated with COVID-19 severity. Keywords. Vitamin D deficiency. SARS-CoV-2. Laboratory parameters. COVID-19. Serum 25(OH)D. RESUMEN Objetivo: la asociación entre la vitamina D y la gravedad de la COVID19 no es consistente. Se comparó la prevalencia y se analizó la asociación de la deficiencia de vitamina D con la gravedad de los pacientes con COVID-19 en el noreste de México. Métodos: este fue un estudio transversal. Se incluyó consecutivamente a individuos de un centro de diagnóstico de referencia durante marzoseptiembre de 2020 (n = 181). Paralelamente, se reclutó a todos los pacientes que ingresaron a cuidados intensivos en ese mismo periodo (n = 116). Se consideró que había deficiencia de vitamina D ante cifras..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit